Next-Generation Bloating Relief.

We are seeking innovative pharmaceutical and non-pharmaceutical solutions for the prevention, management, and relief of bloating, gas, and flatulence, including food supplements, medical devices, and OTC solutions.​

Solutions should be clinically validated, superior to current benchmark options, and supported by relevant regulatory authorization and differentiated claims appropriate to the product category and target market, such as bloating relief and gas/flatulence reduction.​

Solutions should be launch-ready or at an advanced stage of development, with a credible path to commercialization.​

Bloating, gas, and flatulence are among the most common digestive complaints and can significantly impact consumers’ daily comfort and quality of life. Yet existing solutions may deliver inconsistent relief and often fail to fully address consumer expectations for effective, fast, convenient, and reliable symptom management.​

As a global player in digestive wellness, we see an opportunity to bring forward next-generation, clinically validated solutions that better address these unmet needs and offer a clearly differentiated approach to everyday bloating and gas management.​

Must-have Requirements.

• Demonstrated efficacy in bloating and/or gas/flatulence relief, supported by robust human clinical data.​

• Relevant and differentiated bloating-related claims supported by the evidence package and appropriate to the product category and target market.​

• Appropriate regulatory authorization, certification, or a clear regulatory pathway for OTC medicines, medical devices, and/or food supplements, as applicable.​

• Strong scientific rationale supporting the intended benefit.​

• Clear superiority or meaningful differentiation versus relevant benchmark solutions.​

• Launch-ready or advanced-stage solution, with demonstrated manufacturing feasibility and scalability.​
   

Preferred Requirements. ​

• Off-the-shelf finished product available or near-ready for commercialization.​

• Proprietary or protected ingredient, technology, or solution, with a strong IP position or exclusivity potential.​

• Well-characterized mechanism of action.​

• Fast onset and/or long-lasting relief.​
   

Approaches​ not of interest.

• Generic or me-too solutions with limited differentiation versus existing bloating or gas-relief products.​
• Early-stage concepts without robust human clinical validation.​
• Solutions with unclear regulatory feasibility or no credible pathway to support a relevant bloating or gas/flatulence claim.​
• Solutions supported only by preclinical or in vitro evidence.​
• Products with insufficient manufacturing readiness or scalability.​
• Solutions addressing general digestive wellness only, without a specific and substantiated benefit for bloating, gas, or flatulence.​

Target Group​.

Adults and children, no specific health conditions​

Geographies​.

Global